Why the study?
Are beta-blockers associated with a lower rate of cardiac and fatal or near-fatal events in catecholaminergic polymorphic ventricular tachycardia probands and affected family members?
Population
Catecholaminergic polymorphic ventricular tachycardia probands and affected family members
Design
Cohort
Follow-up
long-term
Authors
Loading...
Residual risk persists on beta-blockers in CPVT; leaves open need for adjunctive therapies in prospective trials.
Are beta-blockers associated with a lower rate of cardiac and fatal or near-fatal events in catecholaminergic polymorphic ventricular tachycardia probands and affected family members?
Despite beta-blocker therapy lowering event rates, CPVT patients still experience significant rates of fatal or near-fatal cardiac events, highlighting the need for additional therapies.
Hayashi et al. (2009) studied this question.